Skip to main content

Table 1 Summary of primary neuroendocrine carcinoma of the breast cases published in the indexed literature ( n =83) a

From: Locally-advanced primary neuroendocrine carcinoma of the breast: case report and review of the literature

       Neuroendocrine IHC Hormonal receptors   Treatment   
Author (year) [Ref] Age (years)/Sex Site Size (cm)b TNM IS GML NSE CgA/B Syn NSG ER PR HER2/Neu Neoadjuvant Surgical Adjuvant Follow-up (months) Outcome
Wade (1983) [18] 52/F R 10.0 T4N1M0 - -     + NS NS NS NS Mast/ALND Ch 9 DOD
Jundt (1984) [16] 52/M R NS TxN1M0 NS - +    + NS NS NS NS NS Ch/RT 14 DOD
Papotti (1992) [19] 64/F R 2.0 T1N0M0 + - - - -   - NS NS NS Mast/ALND NS 44 NED
41/F L 3.5 T2NxM0 + - + - - + - NS NS NS Mast/ALND RT 15 DOD
41/F L 3.0 T2NxM0 + + + + + + - NS NS NS Mast/ALND Ch 14 LR/DOD
69/F L 5.0 T3NxM0 + + + - +   + NS NS NS Mast/ALND HT 9 DOD
Papotti (1993) [17] 83/M R 1.5 T1N0M0 + + + +    - NS NS NS Mast NS 84 DOD
Francois (1995) [20] 68/F R 4.5 T2N0M0 NS    +    - - NS - Mast/ALND RT 21 D-NOS
Chua (1997) [21] 45/F L NS T2N0Mx NS NS NS NS NS NS NS NS NS NS BCS NS NS NS
Fukunaga (1998) [22] 56/F R 10.0 T3NxM0 +    + +   - - NS - Mast/ALND - 48 NED
Samli (2000) [23] 60/F L 8.0 T4N1M0 NS    + +   NS NS NS Ch Mast/ALND Ch/RT 6 LR
Shin (2000) [24] 43/F R 1.3 T1NxM0 NS   +     NS NS - - BCS RT 30 NED
44/F L 2.0 T1NxM0 NS   +     NS NS - - BCS/ALND Ch/RT 27 NED
46/F R 3.4 T2NxM0 NS   +     NS NS - - Mast/ALND Ch 11 AWM
50/F R 2.2 T2NxM0 +   +     NS NS - - BCS/ALND Ch/HT 35 NED
51/F R 1.5 T1NxM0 NS   +     NS NS - - BCS/ALND RT 25 NED
57/F L 2.5 T2NxM0 NS   +     NS NS - - Mast/ALND Ch 10 NED
62/F L 5.0 T3NxM0 +   +     NS NS - Ch Mast/ALND Ch/HT 32 AWM
64/F L 1.8 T1NxM0 NS   +     NS NS - - BCS/ALND Ch 10 NED
70/F L 4.0 T2NxM0 +   +     NS NS - - BCS/ALND Ch/RT 3 NED
Yamasaki (2000) [25] 41/F R 4.5 T2N0M0 +    +    - NS NS - BCS/Mast/ALND Ch 16 NED
Salmo (2001) [26] 46/F R 4.0 T2N0M0 + + NS NS NS NS - + NS - BCS Ch/RT 9 NED
Zekioglu (2003) [27] 79/F R 1.5 T1N0M0 +   + + -   + + NS NS Mast/ALND NS 24 NED
76/F L 2.2 T2N0M0 +   + + +   + + NS NS BCS NS 18 NED
65/F R 3.5 T2N0M0 +   + - +   + + NS NS Mast/ALND NS 16 NED
68/F R 7.0 T3N1M0 +   + + +   - - NS NS Mast/ALND NS 22 NED
69/F R 1.0 T1N0M0 +   + + +   + + NS NS Mast/ALND NS 12 NED
72/F R 1.5 T1N0M0 +   + - +   + + NS NS BCS NS 13 NED
60/F R 1.0 T1N0M0 +   + + +   + + NS NS BCS NS 10 NED
43/F L 0.8 T1N0M0 +   + - +   + + NS NS BCS NS 48 NED
60/F L 2.5 T2N0M0 +   + - +   + + NS NS Mast/ALND NS 54 NED
43/F L 5.0 T2N0M0 +   + - +   + + NS NS BCS NS NS NED
72/F L 2.7 T2N0M0 +   + - +   + + NS NS BCS NS NS NED
72/F L 2.7 T2N0M0 +   + - +   + + NS NS Mast/ALND NS NS NED
Bergman (2004) [28] 61/F L 2.5 T2NxM0 +   + - -   - - - - Mast/ALND NS NS NS
Bigotti (2004) [29] 56/F L 18.0 T3N1M0 +   + - +   - - - Ch Mast Ch 14 D-N0S
Jochems (2004) [30] 71/F NS 3.0 T2NxM0 NS   + + +   + + - - Mast/ALND HT 12 NED
Sridhar (2004) [31] 58/F R 2.0 T1NxM0 NS    -    - - NS - BCS/ALND Ch/RT 18 NED
Yamamoto (2004) [32] 53/F NS 6.5 T3N2M0 NS   +     NS NS NS NS NS NS 34 NED
75/F NS 2.0 T2N1M0 NS   +     NS NS NS NS NS NS 43 NED
Berruti (2004) [33] 59/F NS NS T2N0M0 +   + + +   + - NS - Mast HT NS AWM
Adegbola (2005) [34] 46/F R 1.0 T1N0M0 NS    + +   - - - - BCS Ch/RT 48 NED
60/F R 1.7 T1NxM0 +    + +   - - - - BCS Ch/RT 20 D-NOS
61/F L 1.7 T1NxM0 NS    +    - - - - BCS Ch/RT 6 AWM
Valdes (2006) [35] 41/F R/MF 1.5 T1NxM0 +     +   - - NS - Mast/SLNB/Re Ch NS NS
Fujimoto (2007) [36] 40/F L/MF 2.0 T1NxM0 +    + +   + + + - Mast/SLNB HT 36 NED
Kim (2008) [37] 27/F L 3.2 T2NxM0 NS   + + +   NS NS NS - BCS/ALND Ch/RT 18 NED
Kinoshita (2008) [9] 31/F L 6.0 T3NxM0 +   + +    - - - Ch Mast/ALND Ch 9 D-NOS
Stita (2009) [38] 64/F L 3.0 T2NxM0 +   + +    + + NS - Mast/ALND Ch 8 NED
Yamaguchi (2009) [39] 51/F R 3.0 T2NxM0 NS    + +   - - - - Mast/ALND Ch 12 AWM
Christie (2010) [40] 61/F L 3.0 T2NxM0 +    + +   - - - - BCS/ALND Ch 3 D-NOS
Latif (2010) [41] 53 /F R 6.0 T3N0M0 NS    + +   - - - Ch BCS/SLNB RT NS NS
Honami (2011) [42] 54/F B L: 1.0 T1N0M0 L: +    + +   + + - - BCS RT 18 NED
R: 1.5 R: +
Kawanishi (2011) [43] 67/F R 0.8 T1NxM0 +    + +   + + - - BCS/ SLNB HT 12 NED
Nozoe (2011) [44] 57/F R 3.0 T2NxM0 NS   +   +   + + - - Mast/ALND Ch NS NS
Zhang (2011) [45] 29/F B L: 8.5 T1N2M0 L: +   + + +   + + - - BCS Ch NS NS
R: 2.0 R: +
Su (2012) [46] 75/F L 4.0 T2N0M0 NS    + +   + + - - Mast/ALND HT 20 NED
Miura (2012) [47] 72/F R/MC 1.5 T1N0M0 Both +    + +   + + - NS Mast/SLNB NS NS NS
Kawasaki (2012) [48] 41/F L 0.0 TisN0M0 +    + +   + + NS NS BCS NS 101 NED
45/F R 0.0 TisN0M0 +    + +   + + NS NS BCS NS 80 NED
41/F L 0.0 TisN0M0 +    + +   + + NS NS BCS NS 90 NED
74/F R 0.0 TisN0M0 +    + +   + + NS NS BCS NS 91 NED
28/F R 0.0 TisN0M0 +    + +   + + NS NS Mast NS 77 NED
30/F L 0.0 TisN0M0 +    + +   + + NS NS BCS NS 86 NED
58/F R 0.0 TisN0M0 +    + +   + + NS NS BCS NS 96 NED
36/F L 0.0 TisN0M0 +    + +   + + NS NS BCS NS 64 NED
38/F R 0.0 TisN0M0 +    + +   + + NS NS Mast NS 69 NED
60/F L 0.1 T1N0M0 +    + +   + + NS NS BCS NS 84 NED
42/F L 0.1 T1N0M0 +    + +   + + NS NS Mast NS 73 NED
43/F R 0.1 T1N0M0 +    + +   + + NS NS BCS NS 80 NED
35/F R 0.1 T1N0M0 +    + +   + + NS NS BCS NS 100 NED
70/F L 0.1 T1N0M0 +    + +   + + NS NS Mast NS 93 NED
72/F R 0.1 T1N0M0 +    + +   + + NS NS Mast NS 66 NED
62/F L 0.1 T1N0M0 +    + +   + + NS NS BCS NS 88 NED
38/F R 0.2 T1N0M0 +    + +   + + NS NS BCS NS 85 NED
73/F R 0.3 T1N0M0 +    + +   + + NS NS Mast NS 71 NED
43/F L 0.4 T1N1M0 +    + +   + + NS NS BCS NS 86 NED
42/F L 0.5 T1N0M0 +    + +   + + NS NS BCS NS 96 NED
39/F R 0.5 T1N0M0 +    + +   + + NS NS Mast NS 74 NED
33/F R 0.7 T1N0M0 +    + +   + + NS NS Mast NS 92 NED
36/F L 1.5 T1N0M0 +    + +   + + NS NS BCS NS 99 NED
68/F R 2.5 T2N0M0 +    + +   + + NS NS Mast NS 68 NED
(2012) [Present case] 51/F R 2.0 T4aN0M0 +    + +   + - - Ch/RT Mast/ALND Ch/HT 13 AWM
  1. aStudies included in this table are those available in PubMed as of May 31, 2012. Papers that were excluded from this summary are those in which information was not provided explicitly in the description of the case report or because the results were grouped into cohorts [12, 49, 57].
  2. bObtained either from clinical history or the final pathology report; for multifocal or multicentric disease the largest tumor was registered.
  3. ALND, axillary lymph node dissection; AWM, alive with metastatic disease; B, bilateral; BCS, breast conserving surgery; CgA/B, chromogranin A and/or B; Ch, chemotherapy; D-NOS, dead, but cause not otherwise specified; DOD, dead of other disease; ER, estrogen receptors; F, female; GML, Grimelius staining; HT, hormone therapy; IHC, immunohistochemistry; IS, breast in situ component; LR, local recurrence; M, male; Mast, mastectomy; MC, multicentric; MF, multifocal; NED; no evidence of disease; NS, information not specified; NSE, neuron-specific enolase; NSG, neurosecretory granules; PR, progesterone receptors; R, right; Re, reconstruction; RT, radiation therapy; SLNB, sentinel lymph node biopsy; Syn, synaptophysin.